Sugi Predict

Sugi Predict / Compounds / SCHEMBL1733432

SCHEMBL1733432

SCHEMBL1733432

CSc1nc(C(=O)O)cc(=O)[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR84 Q9NQS5 1/20 0.58
▸ POLB P06746 2/20 0.49
▸ PKM P14618 1/20 0.49
▸ KDM6B O15054 1/20 0.44
▸ KDM4A O75164 1/20 0.44
▸ KDM4D Q6B0I6 1/20 0.44
▸ HIF1AN Q9NWT6 1/20 0.44
▸ KDM2A Q9Y2K7 1/20 0.44
▸ ALDH1A1 P00352 4/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ ALOX15 P16050 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ CDC25B P30305 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239284 0.78 MAPT (0.48) PKMMEN1KMT2AMAPT
SCHEMBL1908212 0.76 MEN1 (0.66) GPR84POLBPKMMEN1KMT2A
SCHEMBL12075959 0.76 PDE2A (0.50) GPR84
SCHEMBL18035965 0.75 GPR84 (0.48) GPR84ALDH1A1MEN1KMT2ALMNA
SCHEMBL803563 0.73 PKM (0.54) GPR84POLBPKMALDH1A1LMNA
SCHEMBL18036196 0.73 LMNA (0.47) GPR84POLBALDH1A1LMNAALOX15
SCHEMBL15457569 0.72 PKM (0.53) GPR84POLBPKMALDH1A1MEN1
SCHEMBL5552693 0.72 SCN9A (0.55) POLBPKMALDH1A1MEN1KMT2A
SCHEMBL18931726 0.72 PKM (0.53) POLBPKMMEN1KMT2ALMNA
SCHEMBL3680434 0.72 KDM6B (0.40) GPR84KDM6BKDM4AKDM4DHIF1AN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107635975-B DGAT2 inhibitors 伊莱利利公司 2020-07-24 — — CN disclosed
EP-3087060-B1 PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME (US) 2020-05-13 — — EP disclosed
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 — — EP disclosed
US-10285989-B2 Pyrimidinone amide compounds as PDE2 inhibitors MERCK SHARP & DOHME CORP. (US) 2019-05-14 — — US disclosed
US-20180256575-A1 PYRIMIDINONE AMIDE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-09-13 — — US disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 — — US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 — — US disclosed
EP-3298001-A1 NOVEL DGAT2 INHIBITORS Eli Lilly and Company (US) 2018-03-28 — — EP disclosed
EP-3294297-A1 PYRIMIDINONE AMIDE COMPOUNDS AS PDE2 INHIBITORS Merck Sharp & Dohme Corp. (US) 2018-03-21 — — EP disclosed
US-9815796-B2 Pyrimidone carboxamide compounds as PDE2 inhibitors MERCK SHARP & DOHME CORP. (US) 2017-11-14 — — US disclosed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 — — WO disclosed
EP-1891018-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals, Inc. (US) 2008-02-27 — — EP disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 — — US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 — — US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 — — US disclosed
WO-2006127588-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-11-30 — — WO disclosed
EP-0150507-B1 CEPHALOSPORIN DERIVATIVES, PROCESSES FOR PRODUCING THE SAME AND COMPOSITIONS CONTAINING THEM MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1992-08-05 — — EP disclosed
US-5064953-A INTERMEDIATES CEPHALOSPORIN DERIVATIVES MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1991-11-12 — — US disclosed
US-4888332-A ANTIBIOTICS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1989-12-19 — — US disclosed
EP-0150507-A2 Cephalosporin derivatives, processes for producing the same and compositions containing them MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1985-08-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT GPR84 481/4885POLB 3328/4885PKM 2726/4885
US-10285989-B2 Pyrimidinone amide compounds as PDE2 inhibitors PDE12, PDE2A, PDE4D GPR84 618/4885POLB 740/4885PKM 422/4885
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 GPR84 533/4885POLB 1546/4885PKM 2961/4885
US-20180256575-A1 PYRIMIDINONE AMIDE COMPOUNDS AS PDE2 INHIBITORS PDE12, PDE2A, PDE4D GPR84 618/4885POLB 740/4885PKM 422/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT GPR84 442/4885POLB 3249/4885PKM 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.